NCT06539806Completed
Clinical Study Evaluating the Effect of Losartan
Clinical Study Evaluating the Effect of Losartan on Response Rate in Both Metastatic and Locally Advanced Pancreatic Cancer Patients
Source: ClinicalTrials.gov · Last updated 5 Oct 2026
Brief summary (registry, in English)
The pancreas is two organs packaged into one. The islets of Langerhans serve critical endocrine functions, and the exocrine portion is a major source of enzymes that are essential for digestion. Pancreatic cancer (PC) is more commonly referred to as pancreatic infiltrating ductal adenocarcinoma in addition to being the second leading cause of cancer death in the United States, after lung cancer in 2020. Whereas pancreatic cancer is the seventh cause of death from cancer in Asia in 2020. Although it is substantially less common than the other malignancies, pancreatic carcinoma is near the top of the list of killers because it is a highly aggressive carry.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 90 (actual)
- First submitted
- 18 Jul 2024
- Start date
- 20 Jul 2024
- Primary completion date
- 10 Aug 2026
- Lead sponsor
- Tanta University
- Diseases
- Pancreatic cancer
- NCT number
- NCT06539806
What you commit to
- Study type: Interventional
- Participants enrolled: 90
- From 20 Jul 2024 to the primary completion date, 10 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with serious concomitant systemic disorders as significant cardiac, renal, hepatic, or pulmonary morbidity.
- Patients received prior systemic fluoropyrimidine therapy within the past 10 years.
- Prior un-anticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to 5-fluorouracil, irinotecan, oxaliplatin, losartan, or any monoclonal antibody.
- Patients received a live vaccine or live attenuated vaccines as intranasal influenza vaccines within 30 days of the planned start of study therapy.
Other illness
- Patients with an active, known, or suspected autoimmune disease such as psoriasis.
- Patients with a known positive test for hepatitis B virus surface antigen (HBV s Ag) or hepatitis C virus (HCV antibody) and patients with a known history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS).
Other
- Pregnant or lactating women and women of childbearing potential.
Who the study is looking for
- Male and female pancreatic cancer patients aged ≥ 50 years old.
- Hypertensive patient with BP ≥ 140/90 mm Hg.
- Histologically confirmed metastatic pancreatic adenocarcinoma; or locally advanced pancreatic cancer patients.
- All included patients must sign an informed consent
Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tanta University Hospital Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.